Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;14(12):2848-2863.
doi: 10.1080/21645515.2018.1502126. Epub 2018 Sep 14.

New modalities of allergen immunotherapy

Affiliations

New modalities of allergen immunotherapy

Manish Ramesh et al. Hum Vaccin Immunother. 2018.

Abstract

Allergen immunotherapy is a rapidly evolving field. Although subcutaneous immunotherapy has been practiced for over a hundred years, improved understanding of the underlying immunological mechanisms has led to the development of new, efficacious and better tolerated allergen-derivatives, adjuvants and encapsulated allergens. Diverse routes of allergen immunotherapy - oral, sublingual, epicutanoeus and intralymphatic - are enabling immunotherapy for anaphylactic food allergies and pollen-food allergy syndrome, while improving the tolerability and effectiveness of aeroallergen immunotherapy. The addition of Anti-IgE therapy decreases adverse effects of subcutaneous and oral immunotherapy.

Keywords: Allergen Immunotherapy; Anti-IgE; Epicutaneous Immunotherapy; Oral Immunotherapy; Subcutaneous Immunotherapy; Sublingual Immunotherapy; adjuvants.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Different allergen forms can be administered through a variety of routes eventually leading to similar immunological changes. Subcutaneous – Subcutaneous Immunotherapy, Sublingual – Sublingual Immunotherapy, Oral – Oral Immunotherapy, Epicutanoeus – Epicutaneous Immunotherapy and Intralymphatic – Intralymphatic immunotherapy.

Similar articles

Cited by

References

    1. Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, Agarwal A, Netuveli G, Roberts G, Pfaar O, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597–1631. doi:10.1111/all.13201. - DOI - PubMed
    1. Turkalj M, Banic I, Anzic SA.. A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia). Patient Prefer Adherence. 2017;11:247–257. doi:10.2147/PPA.S70411. - DOI - PMC - PubMed
    1. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1, Supplement):S1–S55. doi:10.1016/j.jaci.2010.09.034. - DOI - PubMed
    1. Fass PT. American academy of otolaryngic allergy endorses the allergen immunotherapy practice parameter. J Allergy Clin Immunol. 2008;121(1):269–70; author reply 270. doi:10.1016/j.jaci.2007.10.030. - DOI - PubMed
    1. Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, Blessing-Moore J, Bernstein D, Dinakar C, Greenhawt M, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28–54. doi:10.1016/j.anai.2016.10.031. - DOI - PubMed

LinkOut - more resources